AR081835A1 - Formas de dosificacion oral de bendamustina - Google Patents
Formas de dosificacion oral de bendamustinaInfo
- Publication number
- AR081835A1 AR081835A1 ARP110101917A ARP110101917A AR081835A1 AR 081835 A1 AR081835 A1 AR 081835A1 AR P110101917 A ARP110101917 A AR P110101917A AR P110101917 A ARP110101917 A AR P110101917A AR 081835 A1 AR081835 A1 AR 081835A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- derivative
- hodgkin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica de administración oral, caracterizada porque la composición comprende bendamustina, o un éster, una sal o un solvato farmacéuticamente aceptable de ésta, como ingrediente activo, y un excipiente farmacéuticamente aceptable que es un agente tensioactivo no iónico, hidrofílico y farmacéuticamente aceptable.Reivindicación 12: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque se usa para tratar una condición médica que se selecciona entre la leucemia linfocítica crónica, la leucemia linfocítica aguda, la leucemia mielocítica crónica, la leucemia mielocítica aguda, la enfermedad de Hodgkin, el linfoma no Hodgkin, el mieloma múltiple, el cáncer de mama, el cáncer de ovario, el cáncer de las células pulmonares pequeñas y el cáncer de las células pulmonares no pequeñas. Reivindicación 13: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque se administra en combinación con al menos un agente activo adicional, donde dicho agente activo adicional se usa antes de la composición farmacéutica, de manera simultánea con ella o después de ella, y se selecciona del grupo que consiste en un anticuerpo con especificidad por CD20, un derivado de antraciclina, un vinca alcaloide o un derivado de platino. Reivindicación 14: La composición farmacéutica de acuerdo con la reivindicación 13, caracterizada porque el anticuerpo con especificidad por CD2O es rituximab, el derivado de antraciclina es doxorrubicina o daunorrubicina, el vinca alcaloide es vincristina y el derivado de platino es cisplatino o carboplatino.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10075231 | 2010-06-02 | ||
EP11075047 | 2011-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081835A1 true AR081835A1 (es) | 2012-10-24 |
Family
ID=44243599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101917A AR081835A1 (es) | 2010-06-02 | 2011-06-02 | Formas de dosificacion oral de bendamustina |
Country Status (25)
Country | Link |
---|---|
US (2) | US20130202693A1 (es) |
EP (1) | EP2575784B1 (es) |
JP (2) | JP6209446B2 (es) |
KR (1) | KR101830142B1 (es) |
CN (1) | CN103037851A (es) |
AR (1) | AR081835A1 (es) |
AU (1) | AU2011260615B2 (es) |
BR (1) | BR112012030654B1 (es) |
CA (1) | CA2800279A1 (es) |
CL (1) | CL2012003341A1 (es) |
CO (1) | CO6640318A2 (es) |
DK (1) | DK2575784T3 (es) |
EA (1) | EA031793B1 (es) |
ES (1) | ES2690257T3 (es) |
IL (1) | IL223311B (es) |
JO (1) | JO3587B1 (es) |
MX (1) | MX2012013872A (es) |
MY (1) | MY173873A (es) |
NZ (1) | NZ603872A (es) |
PL (1) | PL2575784T3 (es) |
PT (1) | PT2575784T (es) |
SG (1) | SG186099A1 (es) |
TW (1) | TWI500431B (es) |
WO (1) | WO2011151087A1 (es) |
ZA (1) | ZA201208823B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2814487A4 (en) * | 2012-02-14 | 2015-07-15 | Eagle Pharmaceuticals Inc | BENDAMUSTIN FORMULATIONS |
EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
WO2013173687A1 (en) * | 2012-05-18 | 2013-11-21 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
AU2013342015B2 (en) | 2012-11-12 | 2016-11-24 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159289C (es) * | 1903-10-08 | 1905-03-16 | ||
US20030044434A1 (en) * | 1997-07-29 | 2003-03-06 | Ping Gao | Self-emulsifying formulation for lipophilic compounds |
FR2781373B1 (fr) * | 1998-07-07 | 2001-09-21 | Pf Medicament | Formulations thixotropes pour le remplissage de gelules |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
EP1379226A2 (en) | 2001-04-10 | 2004-01-14 | Zagros Pharma Inc. | Animal model for evaluating analgesics |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
WO2004069180A2 (en) | 2003-01-31 | 2004-08-19 | Smithkline Beecham Corporation | Solid dispersion compositions |
EP1605916A4 (en) | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
GB0526419D0 (en) | 2005-12-23 | 2006-02-08 | Cyclacel Ltd | Formulation |
WO2008005742A2 (en) * | 2006-06-30 | 2008-01-10 | Mcneil-Ppc, Inc. | Ibuprofen-containing liquid filled hard capsules |
CA2682752C (en) * | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
BRPI0814542A2 (pt) * | 2007-07-12 | 2014-09-30 | Tragara Pharmaceuticals Inc | Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores |
EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
KR100913644B1 (ko) | 2007-10-09 | 2009-08-24 | 제일약품주식회사 | 활성성분으로 시부트라민 유리염기를 함유하는 약제학적조성물 및 그 제조방법 |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CA2726267C (en) * | 2008-06-06 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
EA020354B1 (ru) * | 2008-12-03 | 2014-10-30 | Астеллас Дойчланд Гмбх | Пероральные лекарственные формы бендамустина |
UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
CA2760085A1 (en) | 2009-04-28 | 2010-11-04 | Cephalon, Inc. | Oral formulations of bendamustine |
US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
-
2011
- 2011-06-01 EP EP11727396.1A patent/EP2575784B1/en active Active
- 2011-06-01 JP JP2013512795A patent/JP6209446B2/ja active Active
- 2011-06-01 JO JOP/2011/0180A patent/JO3587B1/ar active
- 2011-06-01 SG SG2012087821A patent/SG186099A1/en unknown
- 2011-06-01 DK DK11727396.1T patent/DK2575784T3/en active
- 2011-06-01 NZ NZ603872A patent/NZ603872A/en unknown
- 2011-06-01 EA EA201291104A patent/EA031793B1/ru unknown
- 2011-06-01 KR KR1020127033697A patent/KR101830142B1/ko active IP Right Grant
- 2011-06-01 CA CA2800279A patent/CA2800279A1/en not_active Abandoned
- 2011-06-01 BR BR112012030654-5A patent/BR112012030654B1/pt not_active IP Right Cessation
- 2011-06-01 WO PCT/EP2011/002764 patent/WO2011151087A1/en active Application Filing
- 2011-06-01 ES ES11727396.1T patent/ES2690257T3/es active Active
- 2011-06-01 US US13/701,269 patent/US20130202693A1/en not_active Abandoned
- 2011-06-01 MX MX2012013872A patent/MX2012013872A/es active IP Right Grant
- 2011-06-01 AU AU2011260615A patent/AU2011260615B2/en active Active
- 2011-06-01 PL PL11727396T patent/PL2575784T3/pl unknown
- 2011-06-01 MY MYPI2012701042A patent/MY173873A/en unknown
- 2011-06-01 CN CN201180037872XA patent/CN103037851A/zh active Pending
- 2011-06-01 PT PT11727396T patent/PT2575784T/pt unknown
- 2011-06-02 TW TW100119389A patent/TWI500431B/zh active
- 2011-06-02 AR ARP110101917A patent/AR081835A1/es not_active Application Discontinuation
-
2012
- 2012-11-22 ZA ZA2012/08823A patent/ZA201208823B/en unknown
- 2012-11-27 IL IL223311A patent/IL223311B/en active IP Right Grant
- 2012-11-29 CL CL2012003341A patent/CL2012003341A1/es unknown
- 2012-12-19 CO CO12230574A patent/CO6640318A2/es unknown
-
2015
- 2015-06-29 US US14/753,483 patent/US10993933B2/en active Active
-
2016
- 2016-06-03 JP JP2016112195A patent/JP6373300B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081835A1 (es) | Formas de dosificacion oral de bendamustina | |
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
AR086412A1 (es) | Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del sintoma tumores de celulas b | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
JP2017008088A5 (es) | ||
CO2017001921A2 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
DOP2010000012A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
AR068862A1 (es) | Terapia de combinacion de un anticuerpo anti- cd20 de tipo ii con un agente activo anti- bcl-2 | |
DOP2012000291A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer de mama | |
RU2016122232A (ru) | Комбинированная терапия на основе антитела к cd20 и ингибитора втк | |
AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CU20130134A7 (es) | Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
JP2012510484A5 (es) | ||
AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
DOP2021000073A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |